Anvatabart opadotin

Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.

A phase III trial of ARX788 showed a significantly longer median progression-free survival (PFS) of 11.3 months compared to 8.2 months with lapatinib plus capecitabine (LC) in HER2-positive advanced breast cancer patients.

Imlunestrant monotherapy significantly improved progression-free survival (PFS) in advanced breast cancer patients with ESR1 mutations compared to standard endocrine therapy.

SHR-A1811, a novel anti-HER2 ADC, shows promising anti-tumor activity and acceptable safety in HR-positive/HER2-low breast cancer in a phase 2 trial.

A meta-analysis of 23 clinical trials reveals the prevalence and distinct toxicity profiles of treatment-related adverse events (TRAEs) associated with currently approved antibody-drug conjugates (ADCs) for metastatic breast cancer. Gastrointestinal disorders were highly prevalent across all treatments, with Trastuzumab Deruxtecan and Sacituzumab Govitecan showing higher symptom burdens compared to Trastuzumab Emtansine. The study underscores the importance of understanding these TRAEs to enhance supportive care and develop personalized risk-stratified care pathways.